Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencySat, 19 Oct 2024 07:43:36 +0200Wed, 02 Oct 2024 13:42:00 +0200Opinion/decision on a Paediatric investigation plan (PIP): Sivextro, tedizolid phosphate, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0340/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001379-pip01-12-m08Opinion/decision on a Paediatric investigation plan (PIP): Sivextro, tedizolid phosphate, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0340/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001379-pip01-12-m08Wed, 02 Oct 2024 13:42:00 +0200Human medicineHuman medicines European public assessment report (EPAR): Sivextro, tedizolid phosphate, Date of authorisation: 23/03/2015, Revision: 24, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/sivextroHuman medicines European public assessment report (EPAR): Sivextro, tedizolid phosphate, Date of authorisation: 23/03/2015, Revision: 24, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/sivextroWed, 24 Jul 2024 15:30:00 +0200Human medicineSivextro : EPAR - All Authorised presentationshttps://www.ema.europa.eu/system/files/documents/all-authorised-presentations/wc500184805_en.pdfSivextro : EPAR - All Authorised presentationshttps://www.ema.europa.eu/system/files/documents/all-authorised-presentations/wc500184805_en.pdfTue, 06 Sep 2016 02:00:00 +0200Human medicine